The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Strategic Procurement Regulations: Navigating South Africa’s 2026 Framework for Pharma and ...
South Africa’s Strategic Procurement Regulations, embedded in the Draft General Public Procurement Regulations, 2026, introduce a structured, data-driven framework that fundamentally changes how public institutions acquire goods and services. For pharmaceutical, biotech and medtech companies, the...
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changing Landscape
EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe's complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organi...
Unlocking the Benefits of Cardiovascular Health Checks in EU Prevention Strategies
Cardiovascular health checks deliver strong clinical, economic and societal value when delivered as structured, risk-based programmes connected to ongoing care. This approach supports EU cardiovascular prevention strategies by catching cardiometabolic risks early and reducing long-term events. Th...